D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 128 Citations 91,465 893 World Ranking 1104 National Ranking 12

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

Reinhard Dummer focuses on Melanoma, Internal medicine, Surgery, Oncology and Cancer research. His research in Melanoma intersects with topics in Cancer, Metastasis, Immunology and Pathology. His study connects Gastroenterology and Internal medicine.

His Surgery research incorporates elements of Placebo and Clinical trial. His Oncology research also works with subjects such as

  • Trametinib and related Dabrafenib,
  • Phases of clinical research which connect with Binimetinib and Tolerability. His biological study spans a wide range of topics, including Cell culture, Gene expression, MAPK/ERK pathway, Neuroblastoma RAS viral oncogene homolog and PTEN.

His most cited work include:

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
  • Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. (2776 citations)

What are the main themes of his work throughout his whole career to date?

Reinhard Dummer mainly investigates Melanoma, Internal medicine, Oncology, Cancer research and Pathology. His study looks at the relationship between Melanoma and topics such as Immunology, which overlap with Cytotoxic T cell. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery.

His studies in Oncology integrate themes in fields like Clinical trial, Phases of clinical research, Trametinib and Dabrafenib. His Cancer research research incorporates themes from Cell, Cell culture, Targeted therapy, Neuroblastoma RAS viral oncogene homolog and MAPK/ERK pathway. His Ipilimumab study combines topics in areas such as Pembrolizumab and Nivolumab.

He most often published in these fields:

  • Melanoma (41.60%)
  • Internal medicine (31.77%)
  • Oncology (24.43%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (31.77%)
  • Melanoma (41.60%)
  • Oncology (24.43%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Melanoma, Oncology, Cancer research and In patient. His Internal medicine study frequently intersects with other fields, such as Trametinib. Reinhard Dummer studies Melanoma, focusing on Binimetinib in particular.

His work deals with themes such as Metastatic melanoma, Radiation therapy, Cutaneous T-cell lymphoma, Phases of clinical research and Survival analysis, which intersect with Oncology. The various areas that Reinhard Dummer examines in his Cancer research study include Downregulation and upregulation, CD8, Neuroblastoma RAS viral oncogene homolog and Kinase, MAPK/ERK pathway. Reinhard Dummer works mostly in the field of Clinical trial, limiting it down to topics relating to Pembrolizumab and, in certain cases, Nivolumab, as a part of the same area of interest.

Between 2018 and 2021, his most popular works were:

  • Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (214 citations)
  • Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. (69 citations)
  • Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma (62 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Reinhard Dummer mainly focuses on Internal medicine, Melanoma, Oncology, Cancer research and Trametinib. His work on Clinical trial, Ipilimumab and Progression-free survival as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Melanoma study incorporates themes from Adjuvant, MEK inhibitor and Immunotherapy.

His work carried out in the field of Oncology brings together such families of science as Phases of clinical research, Survival rate, Adverse effect, Targeted therapy and Biomarker. Reinhard Dummer has researched Cancer research in several fields, including Phenotype, Neuroblastoma RAS viral oncogene homolog, Downregulation and upregulation and MAPK/ERK pathway. His research investigates the connection with Trametinib and areas like Dabrafenib which intersect with concerns in Mutant and Clinical endpoint.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen.
The New England Journal of Medicine (2011)

7772 Citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob.
The New England Journal of Medicine (2015)

5648 Citations

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Frank O. Nestle;Selma Alijagic;Michel Gilliet;Yuansheng Sun.
Nature Medicine (1998)

3676 Citations

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan.
The New England Journal of Medicine (2012)

2181 Citations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski.
The New England Journal of Medicine (2017)

2077 Citations

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski.
The New England Journal of Medicine (2015)

2066 Citations

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan.
The New England Journal of Medicine (2012)

2017 Citations

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla.
Science (2015)

1667 Citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Cory M Johannessen;Jesse S. Boehm;So Young Kim;Sapana R. Thomas;Sapana R. Thomas.
Nature (2010)

1512 Citations

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Elise Olsen;Eric Vonderheid;Nicola Pimpinelli;Rein Willemze.
Blood (2007)

1480 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Reinhard Dummer

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 306

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 296

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 260

John F. Thompson

John F. Thompson

University of Sydney

Publications: 211

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 205

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 204

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 193

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 184

Alexander M. Menzies

Alexander M. Menzies

University of Sydney

Publications: 173

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 172

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Erasmus University Rotterdam

Publications: 172

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 164

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 151

John M. Kirkwood

John M. Kirkwood

University of Pittsburgh

Publications: 149

F. Stephen Hodi

F. Stephen Hodi

Harvard University

Publications: 146

Richard F. Kefford

Richard F. Kefford

Macquarie University

Publications: 146

Trending Scientists

Sebastian Reich

Sebastian Reich

University of Potsdam

Mubashir Husain Rehmani

Mubashir Husain Rehmani

Cork Institute of Technology

Gerard Ghibaudo

Gerard Ghibaudo

Grenoble Alpes University

Nicolas Alonso-Vante

Nicolas Alonso-Vante

University of Poitiers

Jurek Duszczyk

Jurek Duszczyk

Delft University of Technology

Edward J. Kramer

Edward J. Kramer

University of California, Santa Barbara

Curtis H. Flather

Curtis H. Flather

US Forest Service

Umberto Bernabucci

Umberto Bernabucci

Tuscia University

Anthony P. J. Trinci

Anthony P. J. Trinci

University of Manchester

Edward H. Field

Edward H. Field

United States Geological Survey

Jeroen P. van der Sluijs

Jeroen P. van der Sluijs

University of Bergen

John D. Piette

John D. Piette

University of Michigan–Ann Arbor

Eric Taylor

Eric Taylor

King's College London

Martin Peitz

Martin Peitz

University of Mannheim

Samuel Seongseop Kim

Samuel Seongseop Kim

Hong Kong Polytechnic University

Something went wrong. Please try again later.